# A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects

> **NCT05254548** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 22 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ACT-539313
- **DRUG:** Flurbiprofen
- **DRUG:** Omeprazole
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT05254548
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-18
- **Primary completion:** 2022-04-13
- **Final completion:** 2022-04-13
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05254548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05254548, "A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05254548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*